TATE Versus TACE in Intermediate Stage HCC

Carcinoma, Hepatocellular Clinical Trial

— TATE  

Official title:

TATE Versus TACE, an Open-label Randomized Study Comparing TransArterial Tirapazamine Embolization Versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03145558
• Other study ID #: LT-006
• Status: Suspended
• Phase: Phase 2
• Start date: December 5, 2017
• Est. completion date: December 31, 2024

Study information

• Verified date: November 2022
• Source: Teclison Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation. The primary endpoint is Progression Free Survival. Secondary endpoints including CR rate, Time to embolization failure, Duration of CR, OS, ORR, local control rate, time to local recurrence and duration to local recurrence. The study treatment is to compare Tirapazamine versus doxorubicin when combined with trans-arterial embolization. Study plans to enroll 134 patients in 1:1 randomization for TATE or TACE. MRI will be used to assess efficacy using a central radiological review for the final analysis.

Description:

Trans-arterial chemoembolization (TACE) is a standard care of intermediate stage Hepatocellular carcinoma (HCC) for 40 years without much improvement in efficacy. The key reason for lack of progress is that chemotherapy agents are not effective in hypoxia and cancer stem cells are induced under hypoxia. Tirapazamine, a hypoxia activated agent, can potential solve these two problems. This open label randomized trial will be conducted in HCC patients who are in intermediate stage and naive to embolization, Child Pugh up to B7 and with normal organ functions. Patients will be randomized 1:1 to receive TATE (trans-arterial tirapazamine embolization) or conventional TACE. The goal of treatment aims to achieve CR by mRECIST for every patient. If there is evidence of viable lesion, patients should be treated again. All patients are followed by contrast MRI scans every 2 months in the first year and every 3 months afterwards until patients have evidence of progression and no longer considered suitable for TATE/TACE. Survival will be followed for 3 years. Total sample size will be 134 patients with the total study duration for 3 years.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 134
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

1. Confirmed diagnosis of HCC by imaging criteria per American Association for the Study of Liver Diseases (AASLD) criteria.

2. Patients with single or multiple HCC who are unsuitable for surgical resection or RFA, but suitable for embolization.

3. ECOG score 0-1. Child-Pugh score up to B7.

4. Patients should have measurable tumor lesion(s) by contrast MRI.

5. Patients have adequate normal organ function and suitable laboratory criteria.

6. Men and women of child-bearing age need to commit to using two levels of contraception simultaneously to avoid pregnancy.

Exclusion Criteria:

1. Patients who have had a liver transplantation.

2. Patients who have uncontrolled major medical problems such as cardiac, pulmonary (COPD requiring constant oxygen), renal (creatinine over 2.0) diseases, active infectious diseases (except chronic Hepatitis B or C), or non-healing ulceration.

3. Patients who have any clinical evidence of hypoxia with O2 saturation less than 92% on room air.

4. Patients with evidence of arterial insufficiency or microangiopathy in any organ due to any reason, which could lead to distal extremity hypoxia, as evidenced by any gangrenous change in distal limbs or requiring resection for this reason.

5. Patients with poorly controlled HBV infection.

6. Patients on interferon treatment need to have at least 2-week washout period from Day 1.

7. Patients with major gastrointestinal bleeding in the prior 2 months of enrollment or known diagnosis of cancer other than HCC.

8. Pregnant or lactating women.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• Tirapazamine
Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
• Doxorubicin
Standard of care for TACE

Locations

Country	Name	City	State
United States	University of California, Irvine	Irvine	California
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Oregon Health Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Teclison Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Local recurrence rate	Recurrence rate in the embolized lesion	1 year
Other	Time to local recurrence	From randomization to local recurrence	2 years
Primary	Progression Free Survival	mRECIST criteria	within 2 years
Secondary	Overall survival	From randomization to death	3 years
Secondary	Complete Response rate	CR rate based on mRECIST criteria	2 years
Secondary	Time to Embolization Failure	From randomization to stage progression	1 year
Secondary	Duration of CR	From randomization to recurrence in those patients who achieved CR	1 year